Research

IN THIS SECTION 1. Overview 2. Research Focus 3. Projects 4. Publications

 

Publications

 

2008 - 2009

2009

Brophy J, Mukherjee D, Crofford LJ, Peura DA, Lincoff DM, Nissen SE for the PRECISION Investigators. Rationale, design, and governance of PRECISION, a cardiovascular endpoint trial of non-steroidal anti-inflammatory agents (NSAIDS) in patients with arthritis. American Heart Journal 2009, in press.

Truter SL, Catanzaro DF, Borer JS, Lee E, Gupta A, Supino PG, Carter J, Herrold EM, Huang Z, Pitlor LL, Dumlao TF. Extracellular matrix remodeling in aortic regurgitation: role of mitogen-activated protein kinases. Cardiology 2009, in press.

McFarlane SI, Borer JS. Inhibition of the renin angiotesin system and prevention of diabetes and cardiovascular disease: mechanistic insights and lessons learned from clinical trials. Current Diabetes Reports 2009; in press.

Cohn J, Cleland JGF, Lubsen J, Borer JS, Teg PG, Perelman M, Zannad F. Unconventional endpoints in cardiovascular clinical trials: should we be moving away from morbidity and mortality? Journal of Cardiac Failure 2009; in press.

Borer JS. Management decisions in aortic regurgitation: has the time for exercise assessment finally arrived? Journal of the American College of Cardiology: Imaging 2009; in press.

Hennekens CH, DeMets D, Bairey-Merz N, Borzak S, Borer JS. Doing more good than harm: need for a cease fire. American Journal of Medicine 2009; in press.

Sasson L, Ureche A, Manolache G, Ciubotaru A, Borer JS, Schachner A. Nitric oxide synthase inhibitor (MTR-105) during open heart surgery: a double blind placebo controlled study of hemodynamic effect and safety. Cardiology 2009, in press.

Truter SL, Catanzaro DF, Supino PG, Gupta A, Carter JN, Herrold EM, Dumlao TF, Borer, JS. Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts. Cardiology 2009;113:161-168 (DOI: 10.1159/000187723) 

Borer JS. Ischemic mitral regurgitation: the 2007 H.J.C. Swan Memorial Prize in Medical Writing – an editorial. Cardiology 2009;112:243 (DOI: 10.1159/000151692) 

Supino PG, Borer JS, Franciosa JA, Preibisz JJ, Hochreiter CA, Krieger KH, Girardi LN, Bouraad D, Forur L. Acceptability and psychometric properties of the Minnesota Living With Heart Failure questionnaire among patients undergoing heart valve surgery: validation and comparison with SF-36. Journal of Cardiac Failure, 2009, in press.

2008

Borer JS. Heart rate: from risk marker to risk factor. European Heart Journal Supplements 2008;10:Supplement F:F2-F6.

Borer JS, Gordon DJ, Geller NL, Zannad F. When should data and safety monitoring committees share interim results? Journal of the American Medical Association 2008;299:1710-1712.

Bacchetta MD, Salemi A, Milla F, Hong MK, Tio F, Zhou Y, Chen R, Yu F, Southard E, Lee LY, Mack CA, Krieger KH, Isom OW, Ko W, Borer JS, Catanzaro DF. Low-dose spironolactone: effects on artery-to-artery vein grafts and percutaneous coronary intervention sites. American Journal of Therapeutics 2008; in press.

Borer JS, Girardi LN. Repair of the congenitally bicuspid regurgitant aortic valve – a strategic advance. J Am Coll Cardiol 2008;52:50-51.

Lewis RM, Gordon DJ, Poole-Wilson PA, Borer JS, Zannad F. Similarities and differences in design considerations for cell therapy and pharmacologic cardiovascular clinical trials. Cardiology 2008;110:73-80.

Borer JS, LeHeuzey Y. Characterization of the heart rate lowering action of ivabradine, a selective If current inhibitor. American Journal of Therapeutics, 2008, in press.

 

 

 

< Prev

Next >